stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.17
0.10
−1.90%
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) Total debt
Regencell Bioscience Holdings Limited's total debt at the end of fiscal 2023 was $463.7K, down 39.9% from $771.3K in fiscal 2022. Regencell Bioscience Holdings Limited ranks 78th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2023 | $463.7K | (39.88%) |
| FY2022 | $771.3K | (74.88%) |
| FY2020 | $3.1M | 47.46% |
| FY2019 | $2.1M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2023 | $463.7K | (39.88%) |
| Jun 2022 | $771.3K | — |
Total debt against peers
| Company | Total debt |
|---|---|
| PRGO Perrigo Company plc compare | $3.3B |
| PBH Prestige Consumer Healthcare Inc. compare | $2.0B |
| ALVO Alvotech compare | $1.3B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $839.4M |
| TRLV Trulieve Cannabis Corp. compare | $345.0M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $94.5M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $1.4M |
| RGC Regencell Bioscience Holdings Limited | $463.7K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt